A Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Vaccinations of Ad26.RSV.preF One Year Apart in Adults Aged 60 Years and Older in Stable Health
Study Details
Study Description
Brief Summary
The purpose of this study is to assess the safety and tolerability of 2 single doses of either 510^10 viral particles (vp) or 110^11 vp of Ad26.RSV.preF, administered intramuscularly to elderly adults given approximately 12 months apart.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Ad26.RSV.preF 5*10^10 vp (Day 1 and Day 365): Group 1 Participants will receive 5*10^10 viral particles (vp) Ad26.RSV.preF at Day 1 and Day 365 (10 to 13 months after first vaccination). |
Biological: Ad26.RSV.preF 5*10^10 vp
Ad26.RSV.preF will be given at a concentration of 5*10^10 vp/0.5 milliliter (mL).
Other Names:
|
| Experimental: Ad26.RSV.preF 5*10^10 vp (Day 1)- Placebo (Day 365): Group 2 Participants will receive 5*10^10 vp Ad26.RSV.preF at Day 1 and placebo on Day 365 (10 to 13 months after first vaccination). |
Biological: Ad26.RSV.preF 5*10^10 vp
Ad26.RSV.preF will be given at a concentration of 5*10^10 vp/0.5 milliliter (mL).
Other Names:
Drug: Placebo
Participants will receive placebo as formulation buffer.
|
| Experimental: Ad26.RSV.preF 1*10^11 vp (Day 1 and Day 365): Group 3 Participants will receive 1*10^11 vp Ad26.RSV.preF at Day 1 and Day 365 (10 to 13 months after first vaccination). |
Biological: Ad26.RSV.preF 1*10^11 vp
Ad26.RSV.preF will be given at a concentration of 1*10^11 vp/0.5 milliliter (mL).
Other Names:
|
| Experimental: Ad26.RSV.preF 1*10^11 vp (Day 1)- Placebo (Day 365): Group 4 Participants will receive 1*10^11 vp Ad26.RSV.preF at Day 1 and placebo on Day 365 (10 to 13 months after first vaccination). |
Biological: Ad26.RSV.preF 1*10^11 vp
Ad26.RSV.preF will be given at a concentration of 1*10^11 vp/0.5 milliliter (mL).
Other Names:
Drug: Placebo
Participants will receive placebo as formulation buffer.
|
| Experimental: Placebo (Day 1 and Day 365): Group 5 Participants will receive placebo at Day 1 and Day 365 (10 to 13 months after first vaccination). |
Drug: Placebo
Participants will receive placebo as formulation buffer.
|
Outcome Measures
Primary Outcome Measures
- Number of Participants With Solicited Local Adverse Events (AEs) for 7 Days After Each Vaccination (Day 1) [7 days after each vaccination (Day 1)]
- Number of Participants With Solicited Local Adverse Events (AEs) for 7 Days After Each Vaccination (Day 365) [7 days after each vaccination (Day 365)]
- Number of Participants With Solicited Systemic Adverse Events (AEs) for 7 Days After Each Vaccination (Day 1) [7 days after each vaccination (Day 1)]
- Number of Participants With Solicited Systemic Adverse Events (AEs) for 7 Days After Each Vaccination (Day 365) [7 days after each vaccination (Day 365)]
- Number of Participants With Unsolicited AEs for 28 Days After Each Vaccination [28 days after each vaccination (from signing the informed consent form [ICF] to Day 29 inclusive)]
- Number of Participants With Serious Adverse Events (SAEs) Throughout Study [Up to 730 days]
Secondary Outcome Measures
- Respiratory Syncytial Virus (RSV) Neutralization A2 [Days 1, 29, 183, 365, 393, 547, 730]
Analysis of RSV A2 neutralizing titers of the vaccine-induced immune response will be assessed.
- RSV Fusion Protein (F-protein) Enzyme-linked Immunosorbent Assay [Days 1, 29, 183, 365, 393, 547, 730]
Analysis of antibodies binding to RSV F protein in post-fusion and pre-fusion form.
- Intracellular Cytokine Staining [Day 1, 29, 183, 365, 393, 547, 730]
The activation of cluster of differentiation 4 (CD4) and cluster of differentiation 8 (CD8) T-cell subsets and their cytokine expression patterns will be determined by flow cytometry after RSV protein peptide stimulation (including, but not limited to CD4/CD8, interleukin [IL-2], interferon gamma [IFN gamma], tumor necrosis factor alpha [TNF-alpha] and/or activation markers, memory, T-helper [cells] Th1/Th2 subtyping).
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Each participant must sign an informed consent form (ICF) indicating that he or she understands the purpose of and procedures required for the study, is willing to participate in the study and attend all scheduled visits, and is willing and able to comply with all study procedures and adhere to the prohibitions and restrictions specified in this protocol
-
Before randomization, a woman must be: postmenopausal - A postmenopausal state is defined as no menses for 12 months without an alternative medical cause; and not intending to conceive by any methods
-
From the time of first vaccination until 3 months after the first dose of study vaccine, and from the second vaccination through 3 months after, a man who has not had a vasectomy (or if a vasectomy was performed less than 1 year ago and the absence of sperm cannot be verified)
-
In the investigator's clinical judgment, participant must be either in good or stable health. Participants may have underlying illnesses such as hypertension, type 2 diabetes, hyperlipoproteinemia, or hypothyroidism, as long as their symptoms/signs are medically controlled. If they are on medication for a condition, the medication dose must have been stable for at least 12 weeks preceding vaccination and expected to remain stable for the duration of the study. Participants will be included on the basis of physical examination, medical history, vital signs, and 12-lead electrocardiogram (ECG) performed at screening
-
Participant must be healthy on the basis of clinical laboratory tests performed at screening. If the results of the laboratory screening tests are outside the central laboratory normal reference ranges and additionally within the limits of toxicity Grades 1 or 2 according to the US Food and Drug Administration (FDA) toxicity tables (for tests in the FDA table ), the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant and appropriate and reasonable for the population under study. This determination must be recorded in the participant's source documents and initialed by the investigator
Exclusion Criteria:
-
Participant has acute illness (this does not include minor illnesses such as diarrhea) or temperature greater than or equal to (>=) 38.0 degree celsius within 24 hours prior to the first dose of study vaccine; enrollment at a later date is permitted
-
Participant has a serious chronic disorder, including severe chronic obstructive pulmonary disease or clinically significant congestive heart failure, requirement for supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, Alzheimer's disease, or has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (for example, compromise well-being) or that could prevent, limit, or confound the protocol-specified assessments
-
Participant has had major surgery within the 4 weeks prior to randomization or has planned major surgery through the course of the study
-
Participant has chronic active hepatitis B or hepatitis C infection, documented by hepatitis B surface antigen and hepatitis C antibody, respectively
-
Participant has human immunodeficiency virus (HIV) type 1 or type 2 infection
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Miami | Florida | United States |
Sponsors and Collaborators
- Janssen Vaccines & Prevention B.V.
Investigators
- Study Director: Janssen Vaccines & Prevention B.V. Clinical Trial, Janssen Vaccines & Prevention B.V.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CR108214
- VAC18193RSV1003